Cargando…

Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non-small cell lung cancer in vitro and in vivo via the epithelial-to-mesenchymal transition process

Standard chemotherapy is commonly used in clinical practice for the treatment of non-small cell lung cancer (NSCLC). However, its therapeutic efficacy remains low. Combination therapy for cancer treatment has attracted attention in recent years. The present study aimed to investigate the antitumor e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Shanshan, Wang, Rong, Zhang, Xuan, Wu, Feihua, Li, Shengnan, Yuan, Yongfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291674/ https://www.ncbi.nlm.nih.gov/pubmed/32537024 http://dx.doi.org/10.3892/ol.2020.11536

Ejemplares similares

Inhibitory Effects of Plumbagin on Retinal Pigment Epithelial Cell Epithelial-Mesenchymal Transition In Vitro and In Vivo
por: Chen, Haitin, et al.
Publicado: (2018)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
por: Wu, Ying-Si, et al.
Publicado: (2021)

Synergistic Inhibitory Effect of Hyperbaric Oxygen Combined with Sorafenib on Hepatoma Cells
por: Peng, Hai-Shan, et al.
Publicado: (2014)

Sorafenib Inhibits Epithelial-Mesenchymal Transition through an Epigenetic-Based Mechanism in Human Lung Epithelial Cells
por: Zhang, Juyong, et al.
Publicado: (2013)

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Wang, Shanshan, et al.
Publicado: (2023)

Synergistic effects of sorafenib in combination with gemcitabine or pemetrexed in lung cancer cell lines with K-ras mutations
por: Li, Jing, et al.
Publicado: (2016)

Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides
por: Yang, Gang, et al.
Publicado: (2019)

Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation
por: Bort, Alicia, et al.
Publicado: (2017)

Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo
por: Hsu, Fei-Ting, et al.
Publicado: (2015)

Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation
por: Dong, Shuying, et al.
Publicado: (2015)

Sorafenib Ameliorates Renal Fibrosis through Inhibition of TGF-β-Induced Epithelial-Mesenchymal Transition
por: Jia, Lining, et al.
Publicado: (2015)

PDCD2 sensitizes HepG2 cells to sorafenib by suppressing epithelial-mesenchymal transition
por: Liu, Hongyu, et al.
Publicado: (2019)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

Ursolic acid inhibits epithelial-mesenchymal transition in vitro and in vivo
por: Xu, Chang-Geng, et al.
Publicado: (2019)

Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo
por: Shi, Yuqi, et al.
Publicado: (2016)

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition
por: Hu, Bo, et al.
Publicado: (2019)

In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines
por: Adhim, Z, et al.
Publicado: (2011)

Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition
por: Chang, Hongyuan, et al.
Publicado: (2016)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

Activation of autophagy reverses gemcitabine-induced immune inhibition of RAW264.7 macrophages by promoting TNF-α, IL-6 and MHC-II expression
por: Jiang, Shanshan, et al.
Publicado: (2021)

β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling
por: Cao, Zhang-qi, et al.
Publicado: (2019)

Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway
por: Wu, Qiong, et al.
Publicado: (2013)

Emodin reverses resistance to gemcitabine in pancreatic cancer by suppressing stemness through regulation of the epithelial‑mesenchymal transition
por: Wei, Weitian, et al.
Publicado: (2022)

Cortactin in Epithelial–Mesenchymal Transition
por: Ji, Rong, et al.
Publicado: (2020)

Epithelial-Mesenchymal Transition in tumor microenvironment
por: Jing, Yingying, et al.
Publicado: (2011)

Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines
por: LI, JING, et al.
Publicado: (2013)

Salinomycin-Loaded High-Density Lipoprotein Exerts Promising Anti-Ovarian Cancer Effects by Inhibiting Epithelial–Mesenchymal Transition
por: Zou, Miao, et al.
Publicado: (2022)

Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial–mesenchymal transition and acts synergistically with 5-fluorouracil
por: Kurata, Toru, et al.
Publicado: (2018)

Corrigendum: β-Sitosterol and Gemcitabine Exhibit Synergistic Anti-Pancreatic Cancer Activity by Modulating Apoptosis and Inhibiting Epithelial–Mesenchymal Transition by Deactivating Akt/GSK-3β Signaling
por: Cao, Zhang-qi, et al.
Publicado: (2020)

Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial–mesenchymal transition and fibroblast activation
por: Chen, Y-L, et al.
Publicado: (2013)

Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells
por: Xu, Gui-Li, et al.
Publicado: (2020)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Liao, Li-Zhu, et al.
Publicado: (2020)

Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
por: Ma, Jia, et al.
Publicado: (2015)

In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients
por: Mey, V, et al.
Publicado: (2006)

Rescuing SLAMF3 Expression Restores Sorafenib Response in Hepatocellular Carcinoma Cells through the Induction of Mesenchymal-to-Epithelial Transition
por: Fouquet, Grégory, et al.
Publicado: (2022)

IL-6 plays a crucial role in epithelial-mesenchymal transition and pro-metastasis induced by sorafenib in liver cancer
por: Zhang, Ke-Wei, et al.
Publicado: (2021)

Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial–mesenchymal transition
por: Tian, Chuntao, et al.
Publicado: (2022)

SCARA5 inhibits gastric cancer progression via epithelial-mesenchymal transition suppression
por: Zhang, Hangyu, et al.
Publicado: (2021)

Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
por: Shinoda, Shuhei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8ib1c42fhjcqerm42sjporo2j8